PolyPeptide Group AG (FRA:8H0)

Market Cap	1.55B +56.3%
Revenue (ttm)	458.86M +24.4%
Net Income	14.45M
EPS	0.44
Shares Out	n/a
PE Ratio	107.16
Forward PE	44.25
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	46.40
Previous Close	46.40
Day's Range	46.40 - 46.40
52-Week Range	23.40 - 53.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About PolyPeptide Group AG

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services. The company serves academic, ...

• Industry: Commercial Physical and Biological Research
• Founded: 1952
• Employees: 1,460
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8H0

Financial Performance

In 2025, PolyPeptide Group AG's revenue was 389.33 million, an increase of 15.60% compared to the previous year's 336.79 million. Losses were -21.17 million, 8.20% more than in 2024.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error